A personalized medicine approach has been recommended for Alzheimer’s disease (AD).1, 2 One success story for personalized medicine is breast cancer. Separating people with “breast cancer” into groups based on receptors is commonplace today; subtype-specific treatments have reduced mortality.3
A similar strategy may be applicable to AD dementia. Heterogeneity among people with AD dementia may impede research progress into prevention and treatment.4 Identifying more homogeneous subgroups of people with AD dementia may be important in advancing research and may ultimately have therapeutic implications.
